Gene
FBXW7
FBXW7 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (36), Actionable biomarkers (4), Trial mentions (17), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Curated as clinically actionable in cancer by the Cancer Genome Interpreter.
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FBXW7. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 4 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 2 of 8,738 | 0.02% | not measured | |
| 2025 | 5 of 8,875 | 0.06% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 14 of 11,460 | 0.12% |
| 2022 | 0 of 8,285 | 0.00% | 25 of 13,598 | 0.18% |
| 2021 | 2 of 8,692 | 0.02% | 27 of 15,045 | 0.18% |
| 2020 | 0 of 7,640 | 0.00% | 14 of 14,459 | 0.10% |
| 2019 | 2 of 7,300 | 0.03% | 17 of 12,159 | 0.14% |
| 2018 | 1 of 6,927 | 0.01% | 19 of 11,854 | 0.16% |
| 2017 | 0 of 6,558 | 0.00% | 18 of 11,595 | 0.16% |
Showing 10 of 37 years.
Assay-provider ledger (36)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 7 | September 01, 2025 |
| ROCHE DIAGNOSTICS | Context dependent | Clinical validationAnalytical validation | 2 | September 01, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 6 | September 01, 2025 |
| Belay Diagnostics | Diagnostic provider | Clinical validationAnalytical validation | 1 | July 01, 2025 |
| Genetron Health | Diagnostic provider | Clinical validation | 1 | September 27, 2024 |
Showing 5 of 36 assay-provider companies.
Actionable biomarkers (4)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FBXW7 oncogenic mutation | Steroids | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| FBXW7 deletion | Sirolimus | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| FBXW7 deletion | Tubulin Inhibitors | responsive | No disease recorded | Cancer Genome Interpreter |
| FBXW7 oncogenic mutation | Tubulin Inhibitors | responsive | No disease recorded | Cancer Genome Interpreter |
Trial mentions (17)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT03452774 | Trial eligibility (AACT) |
| NCT05605509 | Trial eligibility (AACT) |
| NCT07014917 | Trial eligibility (AACT) |
| NCT07631793 | Trial eligibility (AACT) |
| NCT05687136 | Trial eligibility (AACT) |
Showing 5 of 17 trial mentions.
Target-disease associations (475)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 475 associations.
Vendor sourcing (57)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense changes are a common disease-causing mechanism. In silico ... | View ClinVar record SCV005905165.1 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein ... | View ClinVar record SCV002625021.2 |
| Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | ： Participants meeting all the following criteria may be enrolled 1. Male or female patients aged 18 to 75 years old at the time of signing the informed con... | View trial NCT07631793 |
| Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Trial sponsor | Mentioned in trial textTrial free-text mention | FBXW7 | View trial NCT07631793 |
| Canadian Cancer Trials Group | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have histologically confirmed cancer, that is advanced/metastatic/recurrent or unresectable, for which no curative therapy exists, and be ... | View trial NCT05605509 |
Showing 5 of 57 sourcing records.
Trial-cited literature (223)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma. | Journal of hepatology | 2026 | 2 |
| NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. | Blood | 2024 | 40 |
| Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma. | BMC medicine | 2024 | 38 |
| Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy. | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | 2024 | 1 |
| Biomarkers in Cancer Detection, Diagnosis, and Prognosis. | Sensors (Basel, Switzerland) | 2023 | 222 |
Showing 5 of 223 papers.
Protein variant mentions (4)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G437E | 1 | 2016 | PMID 27879972 |
| p.R505H | 4 | 2015 to 2022 | PMID 35181986, PMID 26619011, PMID 25741868 |
| p.S582L | 1 | 2021 | PMID 33311588 |
| p.V411L | 1 | 2019 | PMID 31340883 |
Human sample screening reference (7)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.G437E | TCGA-LUSC | Adenomas and Adenocarcinomas; Squamous Cell Neoplasms; Bronchus and lung | 1 | 504 | 0.20% | 0.04% to 1.12% |
| p.S582L | CCDI-MCI | Cystic, Mucinous and Serous Neoplasms; Granular Cell Tumors and Alveolar Soft Part Sarcomas; Specialized Gonadal Neoplasms; Neoplasms, NOS; Adenomas and Adenocarcinomas; Gliomas; Meningiomas; Acinar Cell Neoplasms; Odontogenic Tumors; Soft Tissue Tumors and Sarcomas, NOS; Nevi and Melanomas; Malignant Lymphomas, NOS or Diffuse; Epithelial Neoplasms, NOS; Thymic Epithelial Neoplasms; Other and unspecified parts of mouth; Rectosigmoid junction; Thyroid gland; Connective, subcutaneous and other soft tissues; Peripheral nerves and autonomic nervous system; Other endocrine glands and related structures; Retroperitoneum and peritoneum; Vagina; Other and ill-defined digestive organs; Pancreas; Renal pelvis; Bladder; Nasal cavity and middle ear; Meninges; Adrenal gland; Bones, joints and articular cartilage of limbs; Bones, joints and articular cartilage of other and unspecified sites; Breast; Skin; Thymus; Esophagus; Other and ill-defined sites in lip, oral cavity and pharynx; Larynx; Other and unspecified urinary organs; Brain; Testis; Heart, mediastinum, and pleura; Rectum; Nasopharynx; Palate; Prostate gland; Base of tongue; Accessory sinuses; Other and unspecified female genital organs; Lip; Spinal cord, cranial nerves, and other parts of central nervous system; Colon; Oropharynx; Other and ill-defined sites; Unknown; Other and ill-defined sites within respiratory system and intrathoracic organs; Other and unspecified male genital organs; Cervix uteri; Bronchus and lung; Eye and adnexa; Ovary; Small intestine; Lymph nodes; Stomach | 1 | 3,033 | 0.03% | 0.01% to 0.19% |
| p.S582L | CPTAC-2 | Not Reported; Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Ductal and Lobular Neoplasms; Squamous Cell Neoplasms; Other and unspecified female genital organs; Colon; Breast; Retroperitoneum and peritoneum; Rectum; Ovary | 1 | 328 | 0.30% | 0.05% to 1.71% |
| p.S582L | CPTAC-3 | Not Applicable; Transitional Cell Papillomas and Carcinomas; Ductal and Lobular Neoplasms; Adenomas and Adenocarcinomas; Gliomas; Epithelial Neoplasms, NOS; Complex Epithelial Neoplasms; Complex Mixed and Stromal Neoplasms; Lipomatous Neoplasms; Squamous Cell Neoplasms; Myeloid Leukemias; Nevi and Melanomas; Stomach; Other and ill-defined sites in lip, oral cavity and pharynx; Unknown; Colon; Other and unspecified urinary organs; Floor of mouth; Other and unspecified parts of mouth; Gum; Bronchus and lung; Oropharynx; Other and unspecified parts of tongue; Base of tongue; Breast; Other and ill-defined sites; Larynx; Lip; Uterus, NOS; Hematopoietic and reticuloendothelial systems; Kidney; Brain; Skin; Pancreas; Tonsil | 1 | 1,815 | 0.06% | 0.01% to 0.31% |
| p.S582L | HCMI-CMDC | Ductal and Lobular Neoplasms; Complex Mixed and Stromal Neoplasms; Blood Vessel Tumors; Fibromatous Neoplasms; Epithelial Neoplasms, NOS; Mature T- and NK-Cell Lymphomas; Transitional Cell Papillomas and Carcinomas; Complex Epithelial Neoplasms; Squamous Cell Neoplasms; Soft Tissue Tumors and Sarcomas, NOS; Lymphoid Leukemias; Cystic, Mucinous and Serous Neoplasms; Gliomas; Myomatous Neoplasms; Neuroepitheliomatous Neoplasms; Malignant Lymphomas, NOS or Diffuse; Acinar Cell Neoplasms; Osseous and Chondromatous Neoplasms; Synovial-like Neoplasms; Miscellaneous Bone Tumors; Nevi and Melanomas; Adenomas and Adenocarcinomas; Other and unspecified parts of tongue; Stomach; Bronchus and lung; Larynx; Uterus, NOS; Kidney; Esophagus; Other and ill-defined sites; Skin; Colon; Thyroid gland; Bladder; Adrenal gland; Eye and adnexa; Gallbladder; Connective, subcutaneous and other soft tissues; Rectosigmoid junction; Breast; Pancreas; Small intestine; Corpus uteri; Other and unspecified parts of mouth; Liver and intrahepatic bile ducts; Nasal cavity and middle ear; Hematopoietic and reticuloendothelial systems; Brain; Other and unspecified parts of biliary tract; Bones, joints and articular cartilage of other and unspecified sites; Rectum; Unknown; Lymph nodes; Ovary | 3 | 606 | 0.50% | 0.17% to 1.45% |
Showing 5 of 7 cohort observations.
Literature-extracted relations (25)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| BEVACIZUMAB | Chemical | associate |
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. | 2022 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Disease | associate |
NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. | 2024 |
| Rectal Neoplasms | Disease | associate |
Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy. | 2024 |
| Endometrial Neoplasms | Disease | associate |
Fluorescence in situ hybridization test for detection of endometrial carcinoma cells by non-invasive vaginal swab. | 2023 |
| Squamous Cell Carcinoma of Head and Neck | Disease | associate |
The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications. | 2022 |
Showing 5 of 25 relation assertions.
Organizations publishing (283)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 17 | 2010 to 2023 |
| Dana-Farber Cancer Institute | Other | 13 | 2011 to 2022 |
| University of London | Academic | 12 | 2009 to 2022 |
| The University of Texas System | Academic | 11 | 2015 to 2022 |
| Government of the United States of America | Government | 10 | 2013 to 2023 |
Showing 5 of 283 organizations.
Where FBXW7 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- urinary system disease
418 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.